Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 2Recurrence 1Prostatic Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Neurofibromatosis 2 1Meningioma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Glioblastoma 1Estrogen Receptor Positive Breast Cancer 1Disease 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Solid Malignancies 1Advanced Metastatic Breast Cancer 1Advanced Cancer 1Adenocarcinoma 1

Interventions

Irinotecan 2vistusertib 1sapanisertib 1durvalumab 1danvatirsen 1ceralasertib 1cediranib 1ZD4054 1Topotecan 1HM781-36B 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 13-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Solid Malignancies × vistusertib × Clear all
NCT02398747 2024-12-17

Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies

AstraZeneca

Phase 1 Completed
28 enrolled

Advanced Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡